Gracell Biotechnologies

Gracell Biotechnologies

生物技术研究

Shanghai,Shanghai 4,964 位关注者

A Member of the AstraZeneca Group

关于我们

As a member of the AstraZeneca Group, Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing novel autologous and allogeneic cell therapies for cancer and autoimmune diseases. Since its inception, Gracell has established a solid inhouse R&D system. Leveraging its proprietary FasTCAR and TruUCAR technology platforms and SMART CART™ technology modules, Gracell is researching new ways to address current challenges with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal T cell quality and barriers that limit their activity in solid tumors and autoimmune diseases.

所属行业
生物技术研究
规模
201-500 人
总部
Shanghai,Shanghai
类型
私人持股
创立
2017
领域
CAR-T和Cell Therapy

地点

Gracell Biotechnologies员工

动态

  • 查看Gracell Biotechnologies的公司主页,图片

    4,964 位关注者

    Inspiring! 👍 So proud to see AstraZeneca's unwavering pursuit of innovative oncology solutions. Kudos to our commitment to transforming cancer outcomes. As a member of the AZ group , we are equally eager to pioneer more next-gene cell therapies that bring hope to patients. 💪

    查看阿斯利康的公司主页,图片

    3,010,328 位关注者

    We leave ESMO filled with energy and inspiration after connecting with experts and partners from across the globe and exploring emerging treatments that will shape the future of oncology. AstraZeneca is at the forefront of these advancements, pursuing innovative solutions and redefining standards of care to transform outcomes for people with cancer. #ESMO24

    • 该图片无替代文字
  • 查看Gracell Biotechnologies的公司主页,图片

    4,964 位关注者

    Exciting News! 😎 Gracell has secured the prestigious Top Employer Awards: Greater Suzhou Best Employer Selection for the third year in a row! 👍 Our vibrant culture, fueled by collaboration, creativity, and a passion for making a difference, has been recognized once again.   Our innovative capabilities in cell therapy are driving forward advancements with the potential to transform lives. As part of the AstraZeneca family, our dedication to pushing the boundaries of science and delivering potentially life-changing medicines worldwide is unwavering.   🤝 Join us as we continue to attract outstanding minds and provide a nurturing environment for talent to thrive, offering boundless opportunities for growth, learning, and professional development. With our commitment to excellence and innovation, we are poised to help make even greater contributions to develop potentially transformative cell therapies and solutions. #TopEmployer #Gracell #AstraZeneca #Innovation #celltherapy

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • 查看Gracell Biotechnologies的公司主页,图片

    4,964 位关注者

    Congratulations!" Wonderful to see the positive impact of science through AstraZeneca's achievements. Kudos to all involved!"

    查看阿斯利康的公司主页,图片

    3,010,328 位关注者

    We’ve announced our H1 and Q2 results, with the strength of our underlying business providing confidence to upgrade our full-year 2024 guidance. Total Revenue and Core EPS are now anticipated to grow by a mid teens percentage at CER. Thank you to the AstraZeneca team around the world who continue to unlock the power of what science can do for people, society and the planet. #AZN #WhatScienceCanDo

  • Gracell Biotechnologies转发了

    查看Mark Cobbold的档案,图片

    SVP, IO Discovery & Cell Therapy Oncology at AstraZeneca,

    I am thrilled to share the exciting news that Gracell Biotechnologies was nominated as one of the Annual Top 50 Most Innovative Enterprises in the Biopharma Industry in China, and has received the prestigious Pharma BIG Star award!   This is a tremendous achievement and a testament to the efforts, dedication, and innovation of Gracell’s entire team.   The cell therapy pioneers joined the AstraZeneca organization earlier this year and it’s a privilege to be working with such a talented and passionate team as we continue to push the boundaries of science.

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • 查看Gracell Biotechnologies的公司主页,图片

    4,964 位关注者

    Let's work together to constantly push the boundaries of science, pioneer the innovation of cell therapies and deliver life-changing medicines for patients in need. 🤟

    查看阿斯利康的公司主页,图片

    3,010,328 位关注者

    Critical unmet needs remain for many individuals living with blood cancer. Taking courageous, science-based risks is needed to continue to build knowledge and find new solutions for these patients. Share your support for those living with blood cancer. #WorldBloodCancerDay

    • 该图片无替代文字
  • 查看Gracell Biotechnologies的公司主页,图片

    4,964 位关注者

    查看阿斯利康的公司主页,图片

    3,010,328 位关注者

    Today, we revealed our bold ambition to deliver $80bn in annual revenue by 2030, up from $45bn in 2023. This will be achieved through significant growth in our existing oncology, biopharmaceuticals and rare disease portfolio, and by launching 20 new medicines for patients before the end of the decade. And, to drive sustained growth beyond 2030, we’ll continue investing in, and rapidly advancing, transformative new technologies and platforms that will shape the future of medicine. As we enter a new era of growth, we will continue to decouple carbon emissions from our increase in revenue, halving emissions across our value chain by 2030. #AZN #WhatScienceCanDo

  • 查看Gracell Biotechnologies的公司主页,图片

    4,964 位关注者

    #EarthDay As a member of AstraZeneca Group, Gracell Biotechnologies is committed to contributing to a more sustainable future for people, society and the planet. We recognise that adopting circular business approaches and implementing efficient processes to develop and produce our medicines are key to delivering medicines that improve patient outcomes and minimise the burden on the planet. We fully support AstraZeneca’s approach to the circular economy:  • To minimise the amount of materials required and waste generated during manufacture and use of our products • Maximise proportion of waste recycled and aim to eliminate waste to landfill. • Increase reused or recycled content of the materials we use (both directly, and in our supply chain) Find out more about environmental sustainability at AstraZeneca: https://lnkd.in/dW4PBuJr

    • 该图片无替代文字
  • 查看Gracell Biotechnologies的公司主页,图片

    4,964 位关注者

    Today marks a monumental chapter in our journey - we're thrilled to announce that Gracell has entered into a definitive agreement to be acquired by AstraZeneca. This is a testament to our team's relentless dedication and innovative spirit. A heartfelt thank you to our incredible team and supportive partners. Your trust has been integral to our success. Here's to a future filled with growth, innovation, and continued excellence! Find our more here: https://lnkd.in/eUW_m6QV #celltherapy #grcl

    Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases | Gracell Biotechnologies, Inc.

    Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases | Gracell Biotechnologies, Inc.

    ir.gracellbio.com

  • 查看Gracell Biotechnologies的公司主页,图片

    4,964 位关注者

    We are thrilled to announce that our company has received clearance from China's NMPA for our IND application to commence the Phase 1/2 clinical trial of FasTCAR-T GC012F for treating Refractory Systemic Lupus Erythematosus (rSLE). GC012F represents a significant advancement in our commitment to innovative therapeutic solutions. We believe this product has the extensive potential and we seek to offer a more effective and long-lasting treatment option for SLE patients, particularly for those grappling with severe and complex forms of the disease. Stay tuned for more updates as we embark on this exciting journey towards transforming the lives of those affected by lupus! Find out more here: https://lnkd.in/e3piu5WE #celltherapy #GRCL

    • 该图片无替代文字

相似主页

融资